1. Home
  2. ADVM vs CNTB Comparison

ADVM vs CNTB Comparison

Compare ADVM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • CNTB
  • Stock Information
  • Founded
  • ADVM 2006
  • CNTB 2012
  • Country
  • ADVM United States
  • CNTB United States
  • Employees
  • ADVM N/A
  • CNTB N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVM Health Care
  • CNTB Health Care
  • Exchange
  • ADVM Nasdaq
  • CNTB Nasdaq
  • Market Cap
  • ADVM 47.4M
  • CNTB 44.2M
  • IPO Year
  • ADVM 2014
  • CNTB 2021
  • Fundamental
  • Price
  • ADVM $2.17
  • CNTB $0.98
  • Analyst Decision
  • ADVM Strong Buy
  • CNTB Strong Buy
  • Analyst Count
  • ADVM 5
  • CNTB 2
  • Target Price
  • ADVM $23.80
  • CNTB $7.50
  • AVG Volume (30 Days)
  • ADVM 339.0K
  • CNTB 92.2K
  • Earning Date
  • ADVM 08-11-2025
  • CNTB 05-15-2025
  • Dividend Yield
  • ADVM N/A
  • CNTB N/A
  • EPS Growth
  • ADVM N/A
  • CNTB N/A
  • EPS
  • ADVM N/A
  • CNTB N/A
  • Revenue
  • ADVM $1,000,000.00
  • CNTB $26,033,000.00
  • Revenue This Year
  • ADVM N/A
  • CNTB N/A
  • Revenue Next Year
  • ADVM $18.82
  • CNTB N/A
  • P/E Ratio
  • ADVM N/A
  • CNTB N/A
  • Revenue Growth
  • ADVM N/A
  • CNTB N/A
  • 52 Week Low
  • ADVM $1.78
  • CNTB $0.51
  • 52 Week High
  • ADVM $10.14
  • CNTB $1.73
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 44.99
  • CNTB 59.56
  • Support Level
  • ADVM $2.27
  • CNTB $0.91
  • Resistance Level
  • ADVM $2.60
  • CNTB $1.12
  • Average True Range (ATR)
  • ADVM 0.22
  • CNTB 0.08
  • MACD
  • ADVM 0.01
  • CNTB 0.01
  • Stochastic Oscillator
  • ADVM 22.40
  • CNTB 59.26

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: